GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Insmed Inc (FRA:IM8N) » Definitions » Valuation Rank

Insmed (FRA:IM8N) Valuation Rank


View and export this data going back to 2000. Start your Free Trial

What is Insmed Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Insmed Valuation Rank Related Terms

Thank you for viewing the detailed overview of Insmed's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Insmed (FRA:IM8N) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Insmed Inc (FRA:IM8N) » Definitions » Valuation Rank
Comparable Companies
BHVN RARE SWTX ARWR MRUS AXSM XENE CORT FOLD IDYA OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB BNTX XBRU:ARGX
Traded in Other Exchanges
INSM:USA INSM:Mexico IM8N:Germany
Address
700 US Highway 202/206, Bridgewater, NJ, USA, 08807
Website
https://www.insmed.com
Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.